The Launch of the HALO Study at University of Leeds
The University of Leeds has spearheaded a groundbreaking initiative known as the Haematology Lived Experience and Outcomes (HALO) study, the first of its kind in the United Kingdom aimed at comprehensively tracking the lifelong impacts of childhood blood disorders. Announced recently and covered by BBC News, this research project delves into how conditions like sickle cell disease, beta thalassemia, and acute leukaemias affect individuals from childhood into adulthood, examining effects on health, education, employment, and social care. Led through the Child Health Outcomes Research at Leeds (CHORAL) partnership between the university and Leeds Teaching Hospitals NHS Trust, HALO promises to provide vital data to improve patient support and address longstanding health inequalities.
With data linkage already underway since Autumn 2025 and a patient survey launching in January 2026, the study represents a significant advancement in paediatric haematology research. It highlights the pivotal role of UK universities in driving forward medical discoveries that translate directly into better healthcare outcomes.
Key Players: University of Leeds and CHORAL Leadership
At the helm of the HALO study are distinguished academics from the University of Leeds. Professor Richard Feltbower, Professor of Paediatric Epidemiology and Deputy Director of CHORAL, co-leads the project alongside Professor Adam Glaser, Professor of Paediatric Oncology and Late Effects, and Director of CHORAL. Their expertise in linking population health data with real-world outcomes positions the University of Leeds as a leader in child health research.
CHORAL, a collaborative hub funded in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre, facilitates this innovative work by integrating university research with clinical practice at Leeds Children's Hospital. This model exemplifies how higher education institutions foster interdisciplinary teams to tackle complex health challenges. For those interested in similar academic pursuits, opportunities abound in research jobs across UK universities.
Professor Feltbower emphasizes that the study will "shine a light on the experiences of people living with these conditions," underscoring the human element behind the data.
Understanding Childhood Blood Disorders: Sickle Cell Disease
Sickle cell disease (SCD), an inherited genetic disorder affecting red blood cells, causes them to become sickle-shaped, leading to blockages in blood vessels, chronic pain, fatigue, and increased infection risk. In the UK, approximately 17,500 individuals live with SCD, with around 300 babies diagnosed annually, predominantly from African or Caribbean heritage communities. Children with SCD often face hospital admissions for pain crises, blood transfusions, and hydroxyurea treatment to manage symptoms.
The HALO study seeks to quantify how these early challenges influence long-term educational attainment and career prospects, providing evidence for tailored interventions.
Beta Thalassemia: Challenges and Lifelong Management
Beta thalassemia major, another inherited haemoglobinopathy, impairs the production of beta-globin chains, resulting in ineffective red blood cell formation and severe anaemia. UK prevalence stands at about 1,100 cases, with roughly 20 babies born yearly requiring regular blood transfusions and iron chelation therapy to prevent organ damage. Bone marrow transplants offer a potential cure but carry significant risks, as illustrated by patient Kabir Hussain's experience of monthly transfusions from age four and a transplant at ten.
Hussain, now a registered nurse, shares how limited psychological support exacerbated his childhood trauma, a gap HALO aims to illuminate through patient surveys.
Acute Leukaemias: From Cancer Treatment to Survivorship
Acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) are aggressive cancers of white blood cells, representing the most common childhood malignancy in the UK with over 650 diagnoses under age 15 annually. Treatments like chemotherapy and stem cell transplants achieve high survival rates—over 90% for ALL—but survivors face late effects including infertility, cardiac issues, and secondary cancers.
- Step 1: Intensive chemotherapy induction phase targets cancer cells.
- Step 2: Consolidation and maintenance therapy prevents relapse.
- Step 3: Long-term monitoring for survivorship complications.
HALO compares these outcomes to haemoglobinopathies, revealing unique trajectories.
Prevalence Statistics and Regional Context in the UK
In England, newborn screening identifies SCD and thalassemia carriers, yet disparities persist in ethnic minority groups. Northern England, home to HALO collaborators like Haemoglobinopathy Coordinating Centres in Leeds, Newcastle, Bradford, Sheffield, Manchester, and Liverpool, sees higher incidences due to diverse populations.
Health inequalities compound issues: lower access to specialist care correlates with poorer outcomes. This study, linking national data, will map these patterns precisely. For more on UK-focused opportunities, visit our UK higher education resources.
| Condition | UK Prevalence | Annual New Cases (Children) |
|---|---|---|
| Sickle Cell Disease | ~17,500 | ~300 |
| Beta Thalassemia Major | ~1,100 | ~20 |
| Acute Leukaemias | N/A | ~650 |
Study Methodology: Data Linkage and Patient Voices
The HALO approach combines big data analytics with qualitative insights. Researchers link pseudonymised records from NHS digital systems, national cancer registries (e.g., National Cancer Registration and Analysis Service), education databases, and social services across England. This holistic view tracks metrics like school attendance, GCSE results, employment rates, and hospital readmissions.
A parallel survey captures lived experiences, open to diagnosed individuals nationwide. Patients like Solome Mealin, a PhD student at Leeds Beckett University living with SCD, stress the pain crises misunderstood by some clinicians: "Sometimes you feel like a double decker bus is crushing you."
For aspiring researchers, this exemplifies epidemiological methods taught in UK research assistant jobs.
Patient Stories Highlighting Real-World Impacts
Kabir Hussain's journey from frequent transfusions to nursing career showcases resilience, yet he notes, "The majority of people are still suffering and feel forgotten." Solome Mealin advocates for awareness amid stigma, urging survey participation to drive change.
These narratives reveal gaps in psychological support and transition to adult care, common in chronic paediatric conditions. HALO's findings could inform policy, enhancing holistic care pathways.
Funding, Collaborations, and Broader Implications
Secured through a £680,000 grant from Leeds Hospitals Charity, HALO partners with the Sickle Cell Society, UK Thalassemia Society, and regional centres.University of Leeds announcementBBC coverageCHORAL site
Professor Glaser notes the "golden opportunity to address this knowledge gap," potentially improving quality of life and reducing inequalities. In higher education, such projects attract funding and talent, fostering careers in academic CV building.
Addressing Health Inequalities Through Research
Disproportionately affecting ethnic minorities, these disorders expose systemic disparities in UK healthcare access. HALO's population-level analysis will quantify impacts on life expectancy and socioeconomic outcomes, informing equitable policies.
- Reduced school performance due to absences.
- Higher unemployment from chronic fatigue.
- Increased social care needs in adulthood.
This aligns with NIHR priorities, emphasizing university-led solutions.
Career Opportunities in Paediatric Haematology Research
The HALO study underscores demand for experts in epidemiology, oncology, and data science within UK universities. Roles from postdocs to lecturers offer chances to contribute to transformative health research. Explore openings at lecturer jobs or postdoc positions.
Patient advocates like Mealin, pursuing a PhD, demonstrate pathways from lived experience to academia.
Future Outlook: Transforming Care and Policy
By 2030, HALO data could reshape NHS transition programs, gene therapies, and preventive strategies. Participation in the survey empowers patients; results will guide families on prospects.
This exemplifies how university research drives public good, positioning institutions like Leeds as hubs for innovation.
Photo by Alyona Chipchikova on Unsplash
Get Involved and Explore More
Interested in higher education's role in health research? Visit Rate My Professor, browse higher ed jobs, or seek career advice. Share your thoughts below and stay informed on UK academic advancements.
